SEATTLE, April 30 /PRNewswire-FirstCall/ -- Trubion Pharmaceuticals, Inc. (Nasdaq: TRBN) today announced that it plans to issue earnings results for the first quarter ended March 31, 2009, after the close of market on May 7, 2009. The company's earnings conference call will take place May 7, 2009, at 2 p.m. PDT (5 p.m. EDT).
First-Quarter 2009 Earnings Conference Call: 2 p.m. PDT (5 p.m. EDT), May 7, 2009
Trubion will host a conference call and webcast to discuss its financial results in the first quarter, which ended March 31, 2009. The call will be held May 7 at 2 p.m. PDT (5 p.m. EDT). The live event will be available on Trubion's website at http://investors.trubion.com, or by calling (877) 795-3638 or (719) 325-4816. A replay of the discussion will be available from Trubion's website or by calling (888) 203-1112 or (719) 457-0820 and entering 6540657. The telephone replay will be available until midnight, May 14, 2009.
Trubion is a biopharmaceutical company that is creating a pipeline of novel protein therapeutic product candidates to treat autoimmune and inflammatory diseases and cancer. The company's mission is to develop a variety of first-in-class and best-in-class product candidates, customized for optimal safety, efficacy, and convenience that it believes may offer improved patient experiences. Trubion's current product candidates are novel single-chain protein, or SMIP(TM), therapeutics, and are designed using its custom drug assembly technology. Trubion's product pipeline includes CD20-directed SMIP therapeutics such as TRU-015 and SBI-087 for autoimmune and inflammatory diseases, developed under the company's Wyeth collaboration. Trubion's product pipeline also includes Trubion's proprietary product candidate, TRU-016, a novel CD37-targeted therapy for the treatment of B-cell malignancies that is currently in Phase 1/2 clinical evaluation. In addition to Trubion's current clinical stage product pipeline, the company is also developing additional product candidates that build on its product development experience. More information is available in the investors section of Trubion's website: http://investors.trubion.com.
Contact: Jim DeNike Senior Director, Corporate Communications Trubion Pharmaceuticals, Inc. (206) 838-0500 email@example.com http://www.trubion.com Waggener Edstrom Worldwide Healthcare Amy Petty Senior Account Executive (617) 576-5788 firstname.lastname@example.org
|SOURCE Trubion Pharmaceuticals, Inc.|
Copyright©2009 PR Newswire.
All rights reserved